Teva Pharmaceuticals USA Inc. is taking the Biden administration to court over its drug price negotiation program, days before the US government is set to release the next list of drugs selected for ...

Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis ® 2 (ranibizumab) in Europe The partnership broadens Teva's ...

Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report) and increased the price target to $26.00 from $25.00. Discover ...

No significant news for TEVA in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 ...